Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

19.19USD
19 Aug 2019
Change (% chg)

$0.66 (+3.56%)
Prev Close
$18.53
Open
$18.77
Day's High
$19.42
Day's Low
$18.77
Volume
5,653,928
Avg. Vol
8,111,707
52-wk High
$39.59
52-wk Low
$16.63

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 31.22 29.89 32.67
EPS (TTM): 1.23 -- --
ROI: 2.39 14.89 14.48
ROE: 5.71 16.01 15.78

UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

Aug 14 2019

U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

Fidelity battles IRS in court over coal tax credits

BOSTON Fidelity Investments' courtroom battle with the IRS over disallowed tax credits drew to a close on Tuesday when lawyers clashed over whether the mutual fund giant was a bonafide partner in the production of chemically treated coal.

Aug 13 2019

Mylan CEO must sit for new EpiPen litigation deposition - judge

Lawyers for consumers who claim Mylan NV schemed to squelch competition for its EpiPen device may depose its chief executive again after obtaining documents from a company they say agreed to delay the release of a generic version of the emergency allergy treatment.

Aug 05 2019

Mylan reaches $30 million settlement in SEC's EpiPen probe

Mylan NV has reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to its emergency allergy shot EpiPen, which became the center of a firestorm over price increases.

Jul 30 2019

Celgene to pay Mylan $62 million to resolve cancer drug antitrust case

Mylan NV says Celgene Corp will pay it $62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

Jul 30 2019

Tech pulls Wall Street lower on Trump trade warning

NEW YORK Wall Street lost ground on Tuesday after a warning from President Donald Trump to China amid ongoing trade negotiations pressured technology shares, while investors looked to an expected Federal Reserve interest rate cut at the conclusion of its monetary policy meeting. | Video

Jul 30 2019

US STOCKS-Tech pulls Wall Street lower on Trump trade warning

* Indexes off: Dow 0.09%, S&P 500 0.26%, Nasdaq 0.24% (Updates with Apple earnings)

Jul 30 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates